Project Grant R01NS151782
Award Date 8/11/26
Completion Date 5/31/30
Dollars Obligated $589K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, awarded Beth Israel Deaconess Medical Center $749,073 on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate meningeal sensory neuroimmune interactions underlying migraine headache. The research combines expertise in meningeal nociception and migraine pain with functional interactions between nociceptors...
- The National Institute of Neurological Disorders and Stroke awarded Brigham & Women's Hospital $745,570 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the genome-wide association study (GWAS) based neurovascular etiology of migraine and its associated risk of ischemic stroke. The research addresses the gap between recent genetic discoveries identifying 123 migraine susceptibility loci and...
- The National Institute of Neurological Disorders and Stroke awarded Beth Israel Deaconess Medical Center, Inc. $283,037 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds exploratory research investigating the relationship between meningeal nociception and visual cortex hyperexcitability in migraine pathogenesis. The project employs optogenetic activation of meningeal nociceptors, two-photon calcium...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.833 million on July 22, 2026, to investigate the role of TRP ion channels in migraine pain under the Drug Use and Addiction Research Programs (CFDA 93.279). The research examines how TRPV4 calcium ion channels in meningeal mast cells and satellite glial cells contribute to migraine pain and how this contribution varies by sex. The project employs trigeminal neuron–mast cell co-culture techniques, mast cell and...
- Federal Grant Award Summary The University of Virginia received a $444,125 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 18, 2025, with an ultimate completion date of June 30, 2027. The award funds research investigating the role of progesterone receptors in migraine chronification—specifically, the mechanisms by which...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $511,402 on February 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop non-invasive transcutaneous vagus nerve stimulation as a novel neuromodulatory intervention targeting aneurysmal subarachnoid hemorrhage. The project will test whether non-invasive vagus nerve...
- The National Institute of Neurological Disorders and Stroke awarded Olfax, LLC $1,446,740 on September 3, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-addictive intranasal nerve block for rapid acute treatment of migraine and headache disorders. Olfax will develop an intranasal sphenopalatine ganglion (SPG) block procedure targeting the trigeminal nerve to provide acute migraine symptom relief. The project addresses the clinical limitation that existing...
- The National Institute of Neurological Disorders and Stroke, a component of the National Institutes of Health, awarded the University of North Carolina at Chapel Hill $2,676,945 on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research into the allostery of RAMP-CLR (receptor activity modifying protein–calcitonin receptor-like receptor) signaling in vascular cells during migraine. The project employs sophisticated genetic mouse models...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) was awarded $475,475 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 1, 2025, through June 30, 2027. The research project investigates the pathophysiology of morning migraine—migraines characterized by symptom onset between 3–6 AM—with a focus on the relationship...